AP393A - Substituted pipecolinic and acid derivatives as HIV protease inhibitors. - Google Patents

Substituted pipecolinic and acid derivatives as HIV protease inhibitors. Download PDF

Info

Publication number
AP393A
AP393A APAP/P/1993/000495A AP9300495A AP393A AP 393 A AP393 A AP 393A AP 9300495 A AP9300495 A AP 9300495A AP 393 A AP393 A AP 393A
Authority
AP
ARIPO
Prior art keywords
butyl
tert
hydroxy
carboxamide
amino
Prior art date
Application number
APAP/P/1993/000495A
Other languages
English (en)
Other versions
AP9300495A0 (en
Inventor
Paul Cates Anderson
Francois Soucy
Christianneof YOAKIM
Pierre Lavalle
Peirre Louise Beaulieu
Original Assignee
Boehringer Ingelheim Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Canada Ltd filed Critical Boehringer Ingelheim Canada Ltd
Publication of AP9300495A0 publication Critical patent/AP9300495A0/xx
Application granted granted Critical
Publication of AP393A publication Critical patent/AP393A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
APAP/P/1993/000495A 1992-03-13 1993-03-10 Substituted pipecolinic and acid derivatives as HIV protease inhibitors. AP393A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85071692A 1992-03-13 1992-03-13

Publications (2)

Publication Number Publication Date
AP9300495A0 AP9300495A0 (en) 1993-04-30
AP393A true AP393A (en) 1995-08-07

Family

ID=25308925

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1993/000495A AP393A (en) 1992-03-13 1993-03-10 Substituted pipecolinic and acid derivatives as HIV protease inhibitors.

Country Status (25)

Country Link
US (1) US5807870A (fr)
EP (1) EP0560268B1 (fr)
JP (1) JP3258422B2 (fr)
KR (1) KR950700253A (fr)
AP (1) AP393A (fr)
AT (1) ATE116640T1 (fr)
AU (1) AU670582B2 (fr)
CA (1) CA2131185C (fr)
CZ (1) CZ285589B6 (fr)
DE (1) DE69300043T2 (fr)
DK (1) DK0560268T3 (fr)
ES (1) ES2066623T3 (fr)
FI (1) FI944217A0 (fr)
GR (1) GR3015622T3 (fr)
HU (2) HUT70617A (fr)
IL (1) IL105035A (fr)
NO (1) NO302570B1 (fr)
NZ (1) NZ251267A (fr)
OA (1) OA10092A (fr)
PH (1) PH30734A (fr)
PL (1) PL176362B1 (fr)
RU (1) RU2140911C1 (fr)
SK (1) SK280161B6 (fr)
WO (1) WO1993018003A1 (fr)
ZA (1) ZA931776B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
ATE253050T1 (de) 1992-03-11 2003-11-15 Narhex Ltd Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
RU2126794C1 (ru) 1992-03-11 1999-02-27 Нархекс Лимитед Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
JP3657002B2 (ja) 1992-08-25 2005-06-08 ジー．ディー．サール アンド カンパニー レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0610745A3 (en) * 1993-02-09 1994-09-28 Miles Inc Novel aminomethylene derivatives as immunosuppressants.
IL110898A0 (en) * 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2137406C (fr) * 1994-12-06 2005-09-13 Pierre Louis Beaulieu Procede de synthese d'intermediaires essentiels a la preparation d'inhibiteurs de la protease de vih
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5925759A (en) * 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6251906B1 (en) 1998-05-15 2001-06-26 Abbott Laboratories Retroviral protease inhibiting compounds
BR0011864A (pt) 2000-01-19 2004-07-20 Abbott Lab Formulações farmacêuticas
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
ATE343562T1 (de) * 2000-03-23 2006-11-15 Elan Pharm Inc Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
EP1666452A2 (fr) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Composés pour le traitement de la maladie d'Alzheimer
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
DE60112942T2 (de) * 2000-06-30 2006-06-22 Elan Pharmaceuticals, Inc., South San Francisco Verbindungen zur behandlung der alzheimerischen krankheit
MXPA04000140A (es) * 2001-06-27 2004-06-03 Elan Pharm Inc Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer.
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
JP4482883B2 (ja) 2003-05-22 2010-06-16 リードケミカル株式会社 抗ウイルス作用を有する化合物およびその配合剤
EP2301919A1 (fr) * 2004-06-10 2011-03-30 Board of Trustees of Michigan State University Synthèse du caprolactam à partir de la lysine
WO2007015805A1 (fr) * 2005-07-20 2007-02-08 Eli Lilly And Company Composés joints en position 1-amino
EP2148856B8 (fr) * 2007-02-20 2016-04-06 Board of Trustees of Michigan State University Déamination catalytique pour production de caprolactame
JP5448854B2 (ja) 2007-03-12 2014-03-19 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−プロテアーゼ阻害剤複合体
US9095620B2 (en) 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
JP2011529087A (ja) * 2008-07-24 2011-12-01 ドラス コーポレイション 環状アミドモノマーを作製する方法、ならびに関連する誘導体および方法
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346847A2 (fr) * 1988-06-13 1989-12-20 F. Hoffmann-La Roche Ag Dérivés d'amminoacides
EP0432695A2 (fr) * 1989-12-11 1991-06-19 F. Hoffmann-La Roche Ag Dérivés d'acides aminés

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0264106B1 (fr) * 1986-10-14 1994-03-16 Banyu Pharmaceutical Co., Ltd. Dérivés 5-substitués de l'acide amino-4-hydroxy-pentanoique et leur emploi
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
ZA931777B (en) * 1992-03-13 1993-09-23 Bio Mega Boehringer Ingelheim Substituted pyrrolidine derivatives as HIV protease inhibitors.
IL110255A (en) * 1993-07-16 1998-12-06 Merck & Co Inc Creation and resolution of 2 tert-butylcarboxamidopiprazine
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
GB2292146A (en) * 1994-08-11 1996-02-14 Merck & Co Inc HIV protease inhibitors useful for the treatment of AIDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0346847A2 (fr) * 1988-06-13 1989-12-20 F. Hoffmann-La Roche Ag Dérivés d'amminoacides
EP0432695A2 (fr) * 1989-12-11 1991-06-19 F. Hoffmann-La Roche Ag Dérivés d'acides aminés

Also Published As

Publication number Publication date
CZ285589B6 (cs) 1999-09-15
HU9402613D0 (en) 1994-11-28
DE69300043T2 (de) 1995-05-24
CA2131185C (fr) 1997-05-27
ZA931776B (en) 1993-09-24
FI944217A (fi) 1994-09-13
CA2131185A1 (fr) 1993-09-16
ATE116640T1 (de) 1995-01-15
PH30734A (en) 1997-10-17
KR950700253A (ko) 1995-01-16
SK280161B6 (sk) 1999-09-10
JPH0673004A (ja) 1994-03-15
RU2140911C1 (ru) 1999-11-10
EP0560268A1 (fr) 1993-09-15
NO302570B1 (no) 1998-03-23
HUT70617A (en) 1995-10-30
NO943383L (no) 1994-09-12
NO943383D0 (no) 1994-09-12
OA10092A (en) 1996-12-18
AP9300495A0 (en) 1993-04-30
EP0560268B1 (fr) 1995-01-04
DE69300043D1 (de) 1995-02-16
JP3258422B2 (ja) 2002-02-18
SK109094A3 (en) 1995-05-10
PL176362B1 (pl) 1999-05-31
RU94040841A (ru) 1996-07-20
IL105035A0 (en) 1993-07-08
FI944217A0 (fi) 1994-09-13
US5807870A (en) 1998-09-15
GR3015622T3 (en) 1995-06-30
CZ223294A3 (en) 1995-11-15
WO1993018003A1 (fr) 1993-09-16
DK0560268T3 (da) 1995-06-12
HU211854A9 (en) 1995-12-28
NZ251267A (en) 1996-09-25
IL105035A (en) 1997-07-13
ES2066623T3 (es) 1995-03-01
AU3880893A (en) 1993-10-05
AU670582B2 (en) 1996-07-25

Similar Documents

Publication Publication Date Title
AP393A (en) Substituted pipecolinic and acid derivatives as HIV protease inhibitors.
US5521219A (en) Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5734081A (en) Arylthio compounds
US5552405A (en) Substituted pyrrolidine derivatives as HIV protease inhibitors
US5545640A (en) Protease inhibiting succinic acid derivatives
US5614533A (en) Substituted pipecolinic acid derivatives as HIV protease inhibitors
US20050090546A1 (en) Aspartic protease inhibitors
CA2036397C (fr) Inhibiteurs de la protease du vih, renfermant des unites d'amino-acides
Budt et al. HIV protease inhibitor HOE/BAY 793, structure-activity relationships in a series of C2-symmetric diols
EP0687675A2 (fr) Inhibiteurs de la HIV protéase irréversibles, intermédiaires, compositions et procédés pour leur préparation
CA2217030C (fr) Derives d'acide succinique inhibiteurs de protease
US5696134A (en) Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof
CN1096292A (zh) 取代的吡咯烷衍生物用作hiv蛋白抑制剂
CN1096293A (zh) 用作hiv蛋白酶抑制剂的取代2-哌啶酸衍生物